Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Globe Newswire•09/10/2026•08:00 ET
0
Key Highlights
- ➤Nuvectis management to participate in Maxim Growth Summit 2026 on October 14
- ➤Ron Bentsur presenting Immunology & Inflammation Therapies panel at 10:30 AM ET
- ➤Ciprocopan recently approved in China for previously untreated PNH patients
- ➤Nuvectis pipeline includes oncology candidates NXP900 and NXP200
Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.
A webcast of the panel discussion will be available in the Investors section of Nuvectis’ website at www.nuvectis.com.
Get started
Create a free account to read the full story.